Founded in 2016, SpliSense created a platform that harnesses Anti Sense Oligonucleotides (ASO) to treat genetic diseases such as CF.

Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis. The drug is an inhalable version of company’s AAT drug (Alpha-1 Antitrypsin deficiency). The current FDA approval is partly based on successful pre-clinical trials of the […]